INS and metabolic syndrome: However, patients without dyslipidemia (p = 0.009) and those using insulin (< 0.001) appeared to benefit more from RAS-i therapy alone and patients with dyslipidemia (p = 0.009) appear to benefit more from SGLT2-i therapy alone (eFig. 2C).